Entrada Therapeutics (TRDA) EPS (Weighted Average and Diluted) (2022 - 2025)
Historic EPS (Weighted Average and Diluted) for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$1.06.
- Entrada Therapeutics' EPS (Weighted Average and Diluted) fell 20285.71% to -$1.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.56, marking a year-over-year decrease of 26000.0%. This contributed to the annual value of $1.68 for FY2024, which is 94095.73% up from last year.
- Entrada Therapeutics' EPS (Weighted Average and Diluted) amounted to -$1.06 in Q3 2025, which was down 20285.71% from -$1.04 recorded in Q2 2025.
- Entrada Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $1.55 during Q2 2024, with a 5-year trough of -$1.06 in Q3 2025.
- Over the past 4 years, Entrada Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.42 (recorded in 2025), while the average stood at -$0.26.
- Per our database at Business Quant, Entrada Therapeutics' EPS (Weighted Average and Diluted) surged by 42380.95% in 2024 and then tumbled by 20285.71% in 2025.
- Quarter analysis of 4 years shows Entrada Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.78 in 2022, then surged by 64.1% to -$0.28 in 2023, then skyrocketed by 110.12% to $0.03 in 2024, then tumbled by 3841.48% to -$1.06 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$1.06 for Q3 2025, versus -$1.04 for Q2 2025 and -$0.42 for Q1 2025.